Latest News and Press Releases

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tizona Therapeutics, Inc., a privately held, clinical-stage company developing cancer immunotherapies, today announced the initiation...

TTX-080 plus EGFR Inhibitor Cetuximab Demonstrated Promising Evidence of Clinical Activity in Patients with Biomarker-Defined Metastatic Colorectal Cancer and Locally Advanced/Metastatic Head and Neck...

-- Transaction with Gilead Sciences Closed -- -- Tizona Advances TTX-080, a Novel Anti-HLA-G Antibody, with First Patients Treated in Phase I Study – SOUTH SAN FRANCISCO, Calif., Sept. 15, 2020 ...

-- Trishula to Continue Development of TTX-030 in collaboration with AbbVie -- SOUTH SAN FRANCISCO, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Today Trishula Therapeutics, a clinical stage,...

-- IND Cleared by US FDA with Study Enrollment to Begin in Q3 2020 -- -- First Anti-HLA-G Antibody into the Clinic -- SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Tizona...

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Tizona Therapeutics, Inc., a clinical stage, privately held company developing first-in-class cancer immunotherapies, announced today...

SOUTH SAN FRANCISCO, Calif., July 11, 2019 (GLOBE NEWSWIRE) -- Tizona Therapeutics, Inc., a clinical stage, privately held immunotherapy company, today announced the appointment of Joyson...

SOUTH SAN FRANCISCO, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Tizona Therapeutics, Inc., a privately held immunotherapy company, today announced the appointment of Daniel K. Spiegelman to its Board...

SOUTH SAN FRANCISCO, Calif., March 27, 2019 (GLOBE NEWSWIRE) -- Tizona Therapeutics, Inc., a privately held immunotherapy company, today announced that it has begun enrolling patients in its Phase...

– New Leader to Guide Immunotherapy Biotech in its Next Phase of Growth – – FDA Accepts Tizona’s Investigational New Drug Application for TTX-030 – SOUTH SAN FRANCISCO, Calif., Jan. 03, 2019 ...